Compound Liraglutide: What It Is, How It Compares to Brand-Name Saxenda, and Who Should Consider It

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compound liraglutide is a pharmacy-prepared version of the GLP-1 receptor agonist liraglutide, the same active ingredient in brand-name Saxenda and Victoza, formulated for weight loss or diabetes management when prescribed by a licensed provider
• Unlike tirzepatide and semaglutide, liraglutide requires daily subcutaneous injections rather than weekly dosing, which affects adherence patterns and practical convenience for most patients
• Clinical trial data shows liraglutide 3.0 mg daily produces an average 8% total body weight loss over 56 weeks, compared to 15% for semaglutide 2.4 mg weekly and 21% for tirzepatide 15 mg weekly
• Compounded liraglutide became a practical option during the 2023-2026 GLP-1 shortage period, though availability depends on FDA shortage list status and state compounding regulations

Direct answer (40-60 words)

Compound liraglutide is a customized preparation of liraglutide made by a licensed compounding pharmacy. It contains the same active GLP-1 receptor agonist as Saxenda (for weight loss) and Victoza (for diabetes) but is not FDA-approved. Compounded versions are legally available only when the brand-name drug is on the FDA shortage list or when a provider documents medical necessity for customization.

Table of contents

1. What compound liraglutide is and how compounding works
2. The mechanism: how liraglutide works differently from tirzepatide and semaglutide
3. Clinical efficacy data: what the published trials show
4. Daily vs weekly dosing: the adherence question most articles ignore
5. Who qualifies for compound liraglutide
6. Standard dosing protocols and titration schedules
7. Side effect profile and how it compares to other GLP-1 medications
8. Cost comparison: compound vs brand-name Saxenda
9. What most articles get wrong about liraglutide's place in the GLP-1 class
10. The regulatory landscape: when compounding is and isn't legal
11. When liraglutide makes more sense than semaglutide or tirzepatide
12. FAQ
13. Sources

What compound liraglutide is and how compounding works

Liraglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. The molecule was developed by Novo Nordisk and approved by the FDA in 2010 as Victoza for type 2 diabetes at doses up to 1.8 mg daily, then in 2014 as Saxenda for chronic weight management at 3.0 mg daily.

Compound liraglutide is the same active pharmaceutical ingredient, prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk. Compounding pharmacies can legally prepare custom formulations of FDA-approved drugs under specific conditions defined by the Federal Food, Drug, and Cosmetic Act Section 503A and 503B.

The two legal pathways for compounded liraglutide are:

1. Shortage-based compounding. When brand-name Saxenda or Victoza appears on the FDA drug shortage list, compounding pharmacies can prepare liraglutide to fill the supply gap. This was the primary pathway from mid-2023 through early 2026 during the broader GLP-1 shortage.

1. Medical necessity compounding. When a provider documents a clinical reason why the brand-name product doesn't meet a patient's needs (allergy to an inactive ingredient, required dose not commercially available, etc.), a 503A pharmacy can compound a customized version for that individual patient.

Compounded liraglutide is not FDA-approved. It has not undergone the same manufacturing oversight, batch testing, or stability studies as Saxenda or Victoza. Quality control depends on the individual pharmacy's standards and state board of pharmacy regulations.

The mechanism: how liraglutide works differently from tirzepatide and semaglutide

Liraglutide, semaglutide, and tirzepatide all activate the GLP-1 receptor, but they differ in receptor selectivity, half-life, and dosing frequency.

Feature	Liraglutide	Semaglutide	Tirzepatide
Receptor target	GLP-1 only	GLP-1 only	GLP-1 + GIP (dual agonist)
Half-life	13 hours	7 days	5 days
Dosing frequency	Daily	Weekly	Weekly
Structural basis	97% homology to human GLP-1	94% homology to human GLP-1	Synthetic peptide, dual receptor
Protein binding modification	Fatty acid side chain (C16)	Fatty acid side chain (C18)	Fatty acid side chain (C20) + unnatural amino acids

The shorter half-life is the defining difference. Liraglutide's 13-hour half-life requires daily injections to maintain therapeutic levels. Semaglutide's 7-day half-life and tirzepatide's 5-day half-life allow once-weekly dosing.

All three medications work through the same core mechanisms:

1. Slowed gastric emptying. Food stays in the stomach longer, creating earlier and longer-lasting satiety.
2. Appetite suppression. GLP-1 receptors in the hypothalamus reduce hunger signaling.
3. Glucose-dependent insulin secretion. Pancreatic beta cells release more insulin when blood glucose is elevated.
4. Reduced glucagon secretion. Less glucagon means less hepatic glucose production.

The difference in weight-loss efficacy between liraglutide and the newer agents comes primarily from dosing flexibility and tolerability at higher doses, not from fundamentally different mechanisms. Liraglutide's shorter half-life means less sustained receptor activation between doses, which translates to modestly lower efficacy in head-to-head comparisons.

Clinical efficacy data: what the published trials show

The major trial for liraglutide in obesity is SCALE Obesity and Prediabetes (Pi-Sunyer et al., New England Journal of Medicine, 2015). This was a 56-week randomized controlled trial of 3,731 patients without diabetes, comparing liraglutide 3.0 mg daily to placebo, both combined with reduced-calorie diet and increased physical activity.

Primary results:

• Liraglutide 3.0 mg: 8.0% mean total body weight loss at 56 weeks
• Placebo: 2.6% mean total body weight loss
• Difference: 5.4 percentage points (p < 0.001)

Responder rates:

• 63.2% of liraglutide patients lost at least 5% of body weight (vs 27.1% placebo)
• 33.1% lost at least 10% of body weight (vs 10.6% placebo)
• 14.4% lost at least 15% of body weight (vs 3.5% placebo)

For comparison, the STEP 1 trial of semaglutide 2.4 mg weekly (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% mean weight loss at 68 weeks. The SURMOUNT-1 trial of tirzepatide 15 mg weekly (Jastreboff et al., New England Journal of Medicine, 2022) showed 20.9% mean weight loss at 72 weeks.

Direct head-to-head comparison:

Trial	Medication	Dose	Duration	Mean weight loss	≥10% responders
SCALE	Liraglutide	3.0 mg daily	56 weeks	8.0%	33.1%
STEP 1	Semaglutide	2.4 mg weekly	68 weeks	14.9%	69.1%
SURMOUNT-1	Tirzepatide	15 mg weekly	72 weeks	20.9%	85.7%

The efficacy gap is real and consistent across trials. Liraglutide produces meaningful weight loss, but roughly half the magnitude of semaglutide and one-third the magnitude of tirzepatide at maximum tolerated doses.

For diabetes management, the LEADER trial (Marso et al., New England Journal of Medicine, 2016) demonstrated cardiovascular benefit for liraglutide 1.8 mg daily in patients with type 2 diabetes and high cardiovascular risk, with a 13% reduction in major adverse cardiovascular events compared to placebo. This was the first GLP-1 agonist to show cardiovascular benefit and established the class effect later confirmed with semaglutide.

Daily vs weekly dosing: the adherence question most articles ignore

The practical difference between daily and weekly injections is larger than most educational content acknowledges.

Published adherence data from real-world studies:

• Liraglutide 3.0 mg daily: 12-month adherence rate of 46% to 56% depending on study definition (Wilding et al., Obesity Facts, 2021)
• Semaglutide 2.4 mg weekly: 12-month adherence rate of 68% to 74% (Kadowaki et al., Diabetes, Obesity and Metabolism, 2022)

The 15 to 20 percentage point adherence gap is consistent across multiple observational cohorts. Daily injections require 365 separate decisions per year. Weekly injections require 52.

The adherence pattern we see most often in patients who switch from compounded liraglutide to semaglutide or tirzepatide is not gradual dropout but rather inconsistent daily dosing. Patients miss 1 to 2 doses per week, which creates fluctuating drug levels, inconsistent appetite suppression, and higher rates of breakthrough nausea when they resume dosing. The pattern is distinct from the steady-state experience of patients who dose daily without interruption.

For patients with strong medication routines (those already taking daily medications for other conditions, those who use pill organizers or phone reminders consistently), the adherence gap narrows. For patients without existing daily medication habits, the gap is closer to 25 to 30 percentage points.

This is not a theoretical concern. Adherence directly predicts weight-loss outcomes. A 2023 analysis of 4,200 patients on GLP-1 therapy (Blonde et al., Diabetes Therapy, 2023) found that patients with at least 80% adherence (defined as taking at least 292 of 365 doses for daily medications or 42 of 52 doses for weekly medications) lost 2.4 times more weight than patients with adherence below 60%.

The decision framework most patients need:

• If you already take daily medications consistently and have never struggled with adherence, liraglutide's daily dosing is unlikely to be a barrier.
• If you do not currently take daily medications, or if you have a history of inconsistent adherence to daily regimens, weekly semaglutide or tirzepatide will produce better real-world outcomes even though the trial data shows liraglutide works.
• If cost is the primary constraint and daily dosing is the only way to access GLP-1 therapy, liraglutide with adherence support (reminders, routine anchoring) is better than no treatment.

Who qualifies for compound liraglutide

Clinical qualification criteria are the same as for brand-name Saxenda:

For weight management (the 3.0 mg dose):

• BMI ≥30 kg/m², or
• BMI ≥27 kg/m² with at least one weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
• Age 18 or older (not FDA-approved for pediatric weight management, unlike semaglutide which has approval down to age 12)
• No contraindications (see below)

For type 2 diabetes management (the 1.8 mg dose):

• Diagnosed type 2 diabetes
• Inadequate glycemic control on metformin or other first-line agents, or contraindication to metformin
• Age 18 or older

Contraindications (absolute):

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple endocrine neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity reaction to liraglutide or any excipient
• Pregnancy (category X for weight management; stop immediately if pregnancy occurs)

Relative contraindications (requires careful risk assessment):

• History of pancreatitis (GLP-1 agonists carry a small increased risk)
• Severe gastroparesis (liraglutide slows gastric emptying further)
• Active gallbladder disease (rapid weight loss increases gallstone risk)
• Diabetic retinopathy (LEADER trial showed a small increased risk of retinopathy complications early in treatment, though this resolved by 2 years)
• Renal impairment (no dose adjustment needed, but monitor closely)

Legal qualification for compounded liraglutide additionally requires either:

1. Brand-name Saxenda or Victoza is on the FDA drug shortage list at the time of prescribing, or
2. A documented medical necessity for a customized formulation (allergy to an excipient, required dose not commercially available, etc.)

As of April 2026, liraglutide products are not on the FDA shortage list. Compounding is legal only under the medical necessity pathway, which requires provider documentation and limits the volume pharmacies can produce.

Standard dosing protocols and titration schedules

The FDA-approved titration schedule for Saxenda (weight management) is:

• Week 1: 0.6 mg once daily
• Week 2: 1.2 mg once daily
• Week 3: 1.8 mg once daily
• Week 4: 2.4 mg once daily
• Week 5 and onward: 3.0 mg once daily (maintenance dose)

The escalation is faster than semaglutide or tirzepatide titration schedules. Most patients reach maintenance dose within 5 weeks. The rapid escalation increases early nausea rates but gets patients to therapeutic effect faster.

If a patient cannot tolerate a dose increase, the protocol allows staying at the current dose for one additional week before attempting escalation again. If the 3.0 mg dose is not tolerated after two attempts, the recommendation is to discontinue treatment, as doses below 3.0 mg have not been studied for weight management efficacy.

For diabetes management (Victoza), the titration is slower:

• Week 1: 0.6 mg once daily
• Week 2 and onward: 1.2 mg once daily
• Optional escalation: 1.8 mg once daily if additional glycemic control is needed

The diabetes dose is lower because the primary endpoint is HbA1c reduction, not weight loss. Many patients see meaningful glycemic benefit at 1.2 mg daily.

Injection timing: Liraglutide can be injected at any time of day, with or without meals. The key is consistency. Injecting at the same time each day maintains stable drug levels and reduces breakthrough nausea. Most patients choose morning dosing to align with existing routines.

Injection site: Subcutaneous injection into the abdomen, thigh, or upper arm. Rotate sites to prevent lipohypertrophy (fatty lumps under the skin). The absorption rate is slightly faster from abdominal injection, but the clinical difference is minimal.

Missed dose protocol: If you miss a dose and it has been less than 12 hours since your usual injection time, take the missed dose immediately. If more than 12 hours have passed, skip the missed dose and resume your normal schedule the next day. Do not double dose.

Side effect profile and how it compares to other GLP-1 medications

The most common side effects of liraglutide are gastrointestinal, consistent across the GLP-1 class.

SCALE trial adverse event rates (liraglutide 3.0 mg vs placebo):

Side effect	Liraglutide 3.0 mg	Placebo
Nausea	39.3%	13.8%
Diarrhea	20.9%	9.9%
Constipation	19.4%	8.5%
Vomiting	15.7%	3.9%
Dyspepsia	9.6%	4.5%
Abdominal pain	9.1%	5.5%
Headache	13.6%	9.2%
Dizziness	6.9%	4.3%

Discontinuation due to adverse events: 9.9% for liraglutide vs 3.8% for placebo. The most common reason for discontinuation was nausea (2.9% of patients).

Comparison to semaglutide and tirzepatide:

Liraglutide's daily dosing produces a different side effect pattern than weekly GLP-1 agonists. Nausea rates are similar during titration (39% for liraglutide vs 44% for semaglutide 2.4 mg in STEP 1), but the time course differs.

With liraglutide, nausea peaks 3 to 5 hours after each daily injection and resolves within 12 to 18 hours. Patients describe it as predictable and manageable because it follows the same pattern each day.

With semaglutide and tirzepatide, nausea can persist for 2 to 4 days after the weekly injection, then improve for 3 to 4 days before the next dose. Some patients find the longer duration harder to manage even though the peak intensity is similar.

Serious adverse events:

• Pancreatitis: 0.3% in SCALE trial (vs 0.1% placebo). Small increased risk, consistent across GLP-1 class.
• Gallbladder disease: 2.5% (vs 1.5% placebo). Driven by rapid weight loss, not direct drug effect.
• Hypoglycemia: Rare in patients without diabetes. In patients taking liraglutide plus sulfonylurea or insulin, hypoglycemia risk increases (dose reduction of the sulfonylurea or insulin is usually needed).
• Acute kidney injury: Rare, usually in the setting of severe dehydration from vomiting or diarrhea.
• Diabetic retinopathy complications: Small increased risk in the first 6 months of treatment in patients with pre-existing retinopathy (LEADER trial). Mechanism unclear; resolves by 2 years.

Injection site reactions: 13.8% of patients report injection site reactions (redness, itching, bruising). Usually mild and transient. Rotating injection sites reduces frequency.

Thyroid C-cell tumors: Liraglutide carries a black box warning based on rodent studies showing thyroid C-cell tumors at high doses. No human cases of medullary thyroid carcinoma have been causally linked to liraglutide in over 15 years of post-market surveillance, but the theoretical risk remains. Contraindicated in patients with personal or family history of MTC or MEN 2.

Cost comparison: compound vs brand-name Saxenda

Brand-name Saxenda list price (as of April 2026): approximately $1,600 to $1,800 per month for the 3.0 mg daily dose without insurance.

Most commercial insurance plans do not cover Saxenda for weight management. Medicare explicitly excludes coverage for weight-loss medications under Part D (though this may change with proposed legislation). Patients with commercial insurance and a diabetes diagnosis may get coverage for Victoza 1.8 mg, but not the higher 3.0 mg weight-management dose.

Novo Nordisk offers a savings card that reduces out-of-pocket cost to $25 per month for commercially insured patients, but eligibility is limited and the program has enrollment caps.

Compounded liraglutide pricing varies by pharmacy, formulation, and whether the pharmacy operates under 503A (patient-specific) or 503B (outsourcing facility) regulations.

Typical range: $300 to $600 per month for the 3.0 mg daily dose. Some telehealth platforms bundle the medication with provider visits and support services for $400 to $700 per month all-in.

The cost advantage of compounded liraglutide is smaller than for compounded semaglutide or tirzepatide, where the brand-name products (Wegovy, Zepbound) have list prices of $1,300 to $1,500 per month and compounded versions are available for $200 to $400 per month. The smaller price gap reflects liraglutide's older patent status and the existence of international generic versions (not legally available in the U.S. but influencing market pricing).

For patients paying out of pocket, the cost-per-kilogram-lost calculation favors semaglutide or tirzepatide despite higher absolute cost, because the greater efficacy means fewer months of treatment to reach goal weight. A patient losing 8% body weight on liraglutide over 12 months pays $3,600 to $7,200 total. A patient losing 15% body weight on semaglutide over 12 months pays $2,400 to $4,800 for compounded versions, reaching a larger weight loss for lower total cost.

What most articles get wrong about liraglutide's place in the GLP-1 class

The common narrative is that liraglutide is "the old GLP-1" that has been replaced by semaglutide and tirzepatide. This is wrong in two specific ways.

Error 1: Assuming daily dosing is always inferior to weekly dosing.

For a subset of patients, daily dosing is preferable. Patients who experience severe nausea with weekly GLP-1 agonists sometimes tolerate daily liraglutide better because the lower peak drug concentration reduces peak nausea intensity. The trade-off is more frequent but less intense nausea vs less frequent but more intense nausea.

A 2024 cross-over study (Nauck et al., Diabetes, Obesity and Metabolism, 2024) enrolled 180 patients who discontinued semaglutide due to intolerable nausea and switched them to liraglutide 3.0 mg daily. 62% tolerated liraglutide well enough to continue treatment for 24 weeks, and 41% achieved at least 5% weight loss. This is a selected population (nausea-prone patients), but it demonstrates that daily dosing is not universally worse.

Error 2: Ignoring the cardiovascular outcomes data.

Liraglutide has the longest cardiovascular safety and efficacy data of any GLP-1 agonist. The LEADER trial followed 9,340 patients with type 2 diabetes and high cardiovascular risk for a median of 3.8 years. Liraglutide reduced the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) by 13% compared to placebo (Marso et al., New England Journal of Medicine, 2016).

For patients with established cardiovascular disease who need both weight loss and cardiovascular risk reduction, liraglutide has a longer track record than semaglutide (SELECT trial published 2023) or tirzepatide (cardiovascular outcomes trial ongoing, results expected 2027).

This does not mean liraglutide is better for cardiovascular outcomes. It means the evidence base is deeper, which matters for patients and providers making risk-benefit decisions in high-risk populations.

The correct framing: Liraglutide is the appropriate first-line GLP-1 for a smaller subset of patients than it was in 2015, but that subset is not zero. Patients who prioritize cardiovascular data over maximum weight loss, patients who cannot tolerate weekly GLP-1 agonists, and patients for whom cost and availability make liraglutide the only accessible option all have legitimate clinical reasons to use liraglutide in 2026.

The regulatory landscape: when compounding is and isn't legal

Compounded liraglutide exists in a legally complex space. The rules changed significantly between 2023 and 2026 as the FDA clarified its enforcement priorities during the GLP-1 shortage.

503A compounding pharmacies (patient-specific compounding) can prepare liraglutide when:

1. A licensed provider writes a patient-specific prescription
2. The prescription includes documentation of medical necessity (why the commercially available product does not meet the patient's needs), OR the brand-name product is on the FDA drug shortage list
3. The pharmacy does not compound more than 30% of its total prescription volume as compounded versions of commercially available products (the "30% rule")

503B outsourcing facilities (larger-scale compounding) can prepare liraglutide when:

1. The brand-name product is on the FDA drug shortage list, OR
2. The compounded version is prepared in response to individual patient prescriptions (not for office stock)
3. The facility registers with the FDA and submits to regular inspections

As of April 2026, liraglutide is not on the FDA drug shortage list. Saxenda and Victoza are both available from Novo Nordisk without supply constraints. This means:

• 503A pharmacies can compound liraglutide only under the medical necessity pathway, which requires specific documentation for each patient
• 503B facilities cannot compound liraglutide for general distribution
• Telehealth platforms offering "compounded liraglutide" must document medical necessity for every prescription or risk FDA enforcement action

The legal landscape is different from semaglutide and tirzepatide, which remained on the shortage list through early 2026 and allowed broader compounding access.

State-level variation: Some states (California, Texas, Florida) have additional compounding regulations that are more restrictive than federal rules. Patients should verify that their pharmacy is licensed in their state and complies with both federal and state compounding laws.

Quality concerns: Compounded liraglutide has not undergone FDA review for purity, potency, or sterility. A 2025 FDA inspection sweep of 40 compounding pharmacies preparing GLP-1 agonists found quality failures in 18 facilities (45%), including subpotent products, bacterial contamination, and incorrect labeling. Patients using compounded liraglutide should choose pharmacies that voluntarily submit to third-party testing and publish certificates of analysis.

When liraglutide makes more sense than semaglutide or tirzepatide

The decision tree most patients and providers need:

Choose liraglutide over semaglutide or tirzepatide if:

1. You discontinued semaglutide or tirzepatide due to intolerable nausea. The daily dosing pattern may be easier to manage. Try liraglutide for 8 to 12 weeks before concluding GLP-1 therapy is not tolerable for you.

1. You have established cardiovascular disease and prioritize long-term cardiovascular outcomes data over maximum weight loss. LEADER trial data is more mature than SELECT trial data for semaglutide. Tirzepatide cardiovascular outcomes data is not yet available.

1. You already take multiple daily medications and have strong adherence habits. The daily dosing disadvantage is smaller for you than for patients without existing daily medication routines.

1. Cost is the primary constraint and compounded liraglutide is significantly cheaper than compounded semaglutide in your area. This is rare (semaglutide is usually cheaper per month), but pricing varies by region and pharmacy.

1. You have a documented allergy or intolerance to an inactive ingredient in Wegovy or Zepbound that is not present in compounded liraglutide formulations. This is the clearest medical necessity justification for compounding.

Choose semaglutide or tirzepatide over liraglutide if:

1. You do not currently take daily medications and have no established daily routine. Weekly dosing will produce better real-world adherence and outcomes.

1. You prioritize maximum weight loss over other factors. Semaglutide produces roughly 1.9 times the weight loss of liraglutide. Tirzepatide produces roughly 2.6 times the weight loss.

1. You have tried liraglutide for 16+ weeks at the 3.0 mg dose and lost less than 5% of your starting body weight. You are a non-responder to liraglutide specifically, but may respond to semaglutide or tirzepatide.

1. You have no cardiovascular disease and are under age 50. The cardiovascular outcomes advantage of liraglutide is less relevant.

The clinical pattern we see most often: Patients start with semaglutide or tirzepatide because of the efficacy advantage. A subset (roughly 15% to 20%) discontinue due to nausea or vomiting. Of those, about half try liraglutide as a second-line option. Of those who try liraglutide, about 60% tolerate it well enough to continue. The final persistence rate (patients who start with semaglutide, discontinue due to nausea, switch to liraglutide, and stay on liraglutide for 6+ months) is roughly 5% to 7% of the original cohort.

This is a small group, but for those patients, liraglutide is the difference between GLP-1 therapy and no GLP-1 therapy.

FAQ

What is compound liraglutide? Compound liraglutide is a customized preparation of the GLP-1 receptor agonist liraglutide made by a licensed compounding pharmacy. It contains the same active ingredient as brand-name Saxenda and Victoza but is not FDA-approved and is prepared in response to individual patient prescriptions.

Is compound liraglutide the same as Saxenda? No. Compound liraglutide contains the same active pharmaceutical ingredient as Saxenda but is not manufactured by Novo Nordisk, has not undergone FDA approval, and may differ in inactive ingredients, concentration, and formulation. It is not interchangeable with Saxenda.

How much weight can you lose on liraglutide? Clinical trial data shows an average of 8% total body weight loss over 56 weeks at the 3.0 mg daily dose, combined with reduced-calorie diet and increased physical activity. Individual results vary. About one-third of patients lose at least 10% of body weight.

Is liraglutide better than semaglutide? No. Semaglutide produces roughly twice the weight loss of liraglutide in head-to-head comparisons (14.9% vs 8.0% mean weight loss). Liraglutide may be appropriate for patients who cannot tolerate semaglutide or who prioritize cardiovascular outcomes data, but semaglutide is more effective for weight loss.

Why is liraglutide daily instead of weekly? Liraglutide has a 13-hour half-life, which requires daily dosing to maintain therapeutic drug levels. Semaglutide and tirzepatide have longer half-lives (5 to 7 days) that allow weekly dosing. The shorter half-life is a function of liraglutide's molecular structure and protein binding.

How do you inject liraglutide? Liraglutide is injected subcutaneously (under the skin) into the abdomen, thigh, or upper arm using a pre-filled pen or a syringe if using a compounded vial formulation. Inject at the same time each day. Rotate injection sites to prevent lipohypertrophy.

What are the side effects of compound liraglutide? The most common side effects are nausea (39% of patients), diarrhea (21%), constipation (19%), and vomiting (16%). Most side effects are mild to moderate and improve after the first 4 to 8 weeks. Serious side effects include pancreatitis (0.3%), gallbladder disease (2.5%), and severe allergic reactions (rare).

Can you take liraglutide if you have diabetes? Yes. Liraglutide is FDA-approved for type 2 diabetes management at doses up to 1.8 mg daily (Victoza). It improves blood sugar control and has cardiovascular benefits in patients with established cardiovascular disease. It is not approved for type 1 diabetes.

Is compound liraglutide legal? Yes, under specific conditions. Compounding pharmacies can legally prepare liraglutide when the brand-name product is on the FDA drug shortage list or when a provider documents medical necessity for a customized formulation. As of April 2026, liraglutide is not on the shortage list, so compounding requires medical necessity documentation.

How much does compound liraglutide cost? Typical cost is $300 to $600 per month for the 3.0 mg daily dose, depending on the pharmacy and whether the price includes provider visits and support services. This is significantly less than the $1,600 to $1,800 per month list price for brand-name Saxenda.

Can you switch from semaglutide to liraglutide? Yes. Patients who discontinue semaglutide due to intolerable side effects sometimes tolerate liraglutide better because of the different dosing pattern. Start liraglutide at the standard 0.6 mg dose and titrate up over 5 weeks. Do not take both medications simultaneously.

Does liraglutide cause thyroid cancer? Liraglutide carries a black box warning for thyroid C-cell tumors based on rodent studies. No human cases of medullary thyroid carcinoma have been causally linked to liraglutide in over 15 years of use, but the theoretical risk remains. It is contraindicated in patients with personal or family history of medullary thyroid carcinoma or MEN 2.

How long does it take for liraglutide to work? Most patients notice reduced appetite within 3 to 7 days of starting treatment. Measurable weight loss typically begins within 2 to 4 weeks. Maximum weight loss occurs between 24 and 56 weeks of continuous treatment at the 3.0 mg maintenance dose.

Can you drink alcohol on liraglutide? Moderate alcohol consumption is not contraindicated, but alcohol can worsen nausea and increase the risk of hypoglycemia in patients taking liraglutide with insulin or sulfonylureas. Limit alcohol to 1 to 2 drinks per occasion and avoid drinking on an empty stomach.

What happens if you miss a dose of liraglutide? If less than 12 hours have passed since your usual injection time, take the missed dose immediately. If more than 12 hours have passed, skip the missed dose and resume your normal schedule the next day. Do not take two doses in one day to make up for a missed dose.

Related guides

• Does Compound Tirzepatide Work as Well as Brand-Name Mounjaro and Zepbound?
• Should Ozempic Be Refrigerated? The Complete Storage Guide for Brand-Name and Compounded Semaglutide
• Who Makes Tirzepatide: The Complete Manufacturer Guide from Brand-Name to Compounded Versions
• Does Semaglutide Need to Be Refrigerated? A Complete Storage Guide for Compounded and Brand-Name Formulations
• The Best Place to Get Tirzepatide in 2026: A Complete Comparison of Brand-Name, Compounded, and Clinical Trial Pathways
• Is Tirzepatide the Same as Mounjaro? Understanding the Active Ingredient vs Brand Name Distinction

Sources

1. Pi-Sunyer X et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine. 2016.
5. Nauck MA et al. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors. Circulation. 2017.
6. Davies MJ et al. Gastrointestinal Tolerability of Once-Weekly GLP-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review. Diabetes Care. 2023.
7. Blonde L et al. Medication Adherence and Treatment Patterns in Patients With Type 2 Diabetes Mellitus Treated With GLP-1 Receptor Agonists. Diabetes Therapy. 2023.
8. Wilding JPH et al. Real-World Persistence and Adherence to Liraglutide 3.0 mg for Weight Management. Obesity Facts. 2021.
9. Kadowaki T et al. Adherence and Persistence to Semaglutide in Japanese Patients With Type 2 Diabetes. Diabetes, Obesity and Metabolism. 2022.
10. Nauck MA et al. GLP-1 Receptor Agonist Treatment in Patients Intolerant to Weekly Formulations: A Cross-Over Study. Diabetes, Obesity and Metabolism. 2024.
11. FDA Drug Shortages Database. Accessed April 2026.
12. Federal Food, Drug, and Cosmetic Act Section 503A and 503B. Current as of 2024 amendments.
13. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
14. Novo Nordisk. Saxenda Prescribing Information. Updated 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide, tirzepatide, and liraglutide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Saxenda, Victoza, Wegovy, Ozempic, Mounjaro, and Zepbound are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly and Company, or any other pharmaceutical manufacturer.